Regimen library

98 named regimens across 46 cancers: every component with its dose and days, the cycle length and count, emetogenic risk and whether G-CSF is given. Click a regimen for its calendar strip and sources. Reference values from the protocol or label, not a prescription.

98 regimensDownload

	Components		Setting	Trials
177Lu-DOTATATE (PRRT) Lutetium-177 dotatate 7.4 GBq D1; Octreotide LAR 30 mg D1	Lutetium-177 dotatate, Octreotide LAR	every 56 days × 4	SSTR-positive gastroenteropancreatic NET after somatostatin analogue	COMPETE
177Lu-PSMA-617 Lutetium-177 vipivotide tetraxetan 7.4 GBq D1	Lutetium-177 vipivotide tetraxetan	every 42 days × 6	PSMA PET-positive metastatic castration-resistant prostate cancer after an AR-pathway inhibitor (PSMAfore) and, in VISION, after taxane	VISION, PSMAfore, PSMAddition
7+3 (cytarabine + anthracycline) ± midostaurin Cytarabine 100-200 mg/m² per day D1-7 (168 h infusion); Daunorubicin 60-90 mg/m² or idarubicin 12 mg/m² daily D1-3; Midostaurin (FLT3-mutated) 50 mg twice daily D8-21	Cytarabine, Daunorubicin 60-90 mg/m² or idarubicin 12 mg/m², Midostaurin	every 28 days × 1-2	Fit adults with newly diagnosed AML; midostaurin for FLT3-mutated disease (quizartinib for FLT3-ITD)	RATIFY (CALGB 10603), QuANTUM-First
Abiraterone + prednisone with ADT Abiraterone acetate 1,000 mg once daily on an empty stomach D1-28; Prednisone 5 mg once daily (twice daily in castration-resistant disease) D1-28; GnRH agonist or antagonist per depot schedule D1	Abiraterone acetate, Prednisone, GnRH agonist or antagonist	every 28 days	High-risk metastatic hormone-sensitive (LATITUDE, STAMPEDE) or castration-resistant prostate cancer	LATITUDE, STAMPEDE
ABVD Doxorubicin 25 mg/m² D1, 15; Bleomycin 10 units/m² D1, 15; Vinblastine 6 mg/m² D1, 15; Dacarbazine 375 mg/m² D1, 15	Doxorubicin, Bleomycin, Vinblastine, Dacarbazine	every 28 days × 2-6	Classical Hodgkin lymphoma: 2-4 cycles early stage (PET-adapted), 6 cycles advanced stage	RATHL
APT (weekly paclitaxel + trastuzumab) Paclitaxel 80 mg/m² D1; Trastuzumab 4 mg/kg loading then 2 mg/kg weekly; 6 mg/kg every 3 weeks after chemotherapy D1	Paclitaxel, Trastuzumab	weekly × 12	Stage I HER2-positive breast cancer, node-negative, tumour 3 cm or smaller	APT (adjuvant paclitaxel-trastuzumab)
Atezolizumab + bevacizumab Atezolizumab 1,200 mg D1; Bevacizumab 15 mg/kg D1	Atezolizumab, Bevacizumab	every 21 days	Unresectable hepatocellular carcinoma, Child-Pugh A, varices treated	IMbrave150
ATRA + arsenic trioxide Tretinoin (ATRA) 45 mg/m² per day in two doses D1-28; Arsenic trioxide 0.15 mg/kg per day D1-28	Tretinoin, Arsenic trioxide	every 28 days	Low or intermediate-risk acute promyelocytic leukaemia (WBC 10 × 10⁹/L or less)	none
Bendamustine + rituximab (BR) Bendamustine 90 mg/m² (70 mg/m² in CLL combinations) D1, 2; Rituximab 375 mg/m² D1	Bendamustine, Rituximab	every 28 days × 6	Indolent lymphoma and mantle cell lymphoma first line; fit CLL without del(17p) where targeted agents are unavailable	none
BEP Bleomycin 30 units D1, 8, 15; Etoposide 100 mg/m² D1-5; Cisplatin 20 mg/m² D1-5	Bleomycin, Etoposide, Cisplatin	every 21 days × 3	Metastatic germ cell tumour: 3 cycles good risk, 4 cycles intermediate or poor risk	none
Blinatumomab Blinatumomab 28 µg/day continuous infusion (9 µg/day days 1-7 of cycle 1 in relapsed disease) D1-28 (672 h infusion)	Blinatumomab	every 42 days × 2	B-ALL: MRD-positive, relapsed/refractory, or consolidation in frontline regimens (E1910, AALL1731)	TOWER, ECOG-ACRIN E1910, COG AALL1731
BV-AVD Brentuximab vedotin 1.2 mg/kg D1, 15; Doxorubicin 25 mg/m² D1, 15; Vinblastine 6 mg/m² D1, 15; Dacarbazine 375 mg/m² D1, 15	Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine	every 28 days × 6	Stage III-IV classical Hodgkin lymphoma	ECHELON-1
Cabazitaxel + prednisone Cabazitaxel 20 mg/m² (25 mg/m² in selected patients) D1; Prednisone 10 mg once daily D1-21	Cabazitaxel, Prednisone	every 21 days	Metastatic castration-resistant prostate cancer after docetaxel and an AR-pathway inhibitor	none
Capecitabine (post-neoadjuvant) Capecitabine 1,250 mg/m² twice daily D1-14	Capecitabine	every 21 days × 6-8	Residual invasive disease after neoadjuvant chemotherapy, HER2-negative	none
CAPOX XELOX Oxaliplatin 130 mg/m² D1; Capecitabine 1,000 mg/m² twice daily D1-14	Oxaliplatin, Capecitabine	every 21 days × 4	Adjuvant stage III colon (3 or 6 months), rectal total neoadjuvant therapy, metastatic first line	none
CAPTEM Capecitabine 750 mg/m² twice daily D1-14; Temozolomide 200 mg/m² D10-14	Capecitabine, Temozolomide	every 28 days	Advanced pancreatic neuroendocrine tumour	none
Carboplatin + etoposide + atezolizumab (or durvalumab) Carboplatin AUC 5 D1; Etoposide 100 mg/m² D1-3; Atezolizumab 1,200 mg (IMpower133) or durvalumab 1,500 mg (CASPIAN) day 1; maintenance every 3-4 weeks D1	Carboplatin, Etoposide, Atezolizumab 1,200 mg	every 21 days × 4	Extensive-stage SCLC, first line	IMpower133, CASPIAN, IMforte
Carboplatin + paclitaxel Carboplatin AUC 5-6 D1; Paclitaxel 175 mg/m² D1	Carboplatin, Paclitaxel	every 21 days × 6	Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC	RUBY / ENGOT-EN6 / GOG-3031, NRG-GY018 / KEYNOTE-868, DUO-E / GOG-3041 / ENGOT-EN10
Carboplatin + paclitaxel + bevacizumab, then bevacizumab maintenance Carboplatin AUC 6 D1; Paclitaxel 175 mg/m² D1; Bevacizumab 15 mg/kg (7.5 mg/kg in ICON7), from cycle 2 D1	Carboplatin, Paclitaxel, Bevacizumab	every 21 days × 6	Stage III-IV ovarian cancer, especially with residual disease or ascites	GOG-0218 & ICON7 (bevacizumab), PAOLA-1 / ENGOT-ov25
CDK4/6 inhibitor + aromatase inhibitor Palbociclib 125 mg or ribociclib 400-600 mg once daily days 1-21 of 28 D1-21; Abemaciclib (alternative) 150 mg twice daily continuously D1-28; Letrozole 2.5 mg once daily D1-28	Palbociclib 125 mg or ribociclib 400-600 mg once daily, Abemaciclib, Letrozole	every 28 days	HR-positive, HER2-negative advanced breast cancer, first line (and adjuvant abemaciclib or ribociclib for high-risk early disease)	PALOMA-2, MONALEESA-2, MONARCH 3, monarchE, NATALEE
Chemoradiation then durvalumab (PACIFIC) Durvalumab 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks D1	Durvalumab	every 28 days × 12	Unresectable stage III NSCLC without progression after platinum-based chemoradiation	PACIFIC
Cisplatin + etoposide (EP) Cisplatin 75 mg/m² D1; Etoposide 100 mg/m² D1-3	Cisplatin, Etoposide	every 21 days × 4	Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma	ADRIATIC, CONVERT
Cisplatin + pemetrexed Cisplatin 75 mg/m² D1; Pemetrexed 500 mg/m² D1	Cisplatin, Pemetrexed	every 21 days × 6	Unresectable pleural mesothelioma (with or without bevacizumab); non-squamous NSCLC	MAPS, BEAT-meso (ETOP 13-18)
Cisplatin + vinorelbine (adjuvant) Cisplatin 50 mg/m² D1, 8; Vinorelbine 25 mg/m² D1, 8, 15, 22	Cisplatin, Vinorelbine	every 28 days × 4	Completely resected stage IB (4 cm or larger) to IIIA NSCLC	none
CROSS chemoradiation Carboplatin AUC 2 D1; Paclitaxel 50 mg/m² D1; Radiotherapy 1.8 Gy per fraction, 5 days a week D1-5	Carboplatin, Paclitaxel, Radiotherapy	weekly × 5	Resectable oesophageal or junctional cancer (T1N1 or T2-3N0-1), before surgery	CROSS, CheckMate 577
D-VRd (PERSEUS) Daratumumab 1,800 mg weekly cycles 1-2, every 2 weeks cycles 3-6, every 4 weeks thereafter D1, 8, 15, 22; Bortezomib 1.3 mg/m² D1, 4, 8, 11; Lenalidomide 25 mg once daily D1-21; Dexamethasone 40 mg D1, 2, 3, 4, 9, 10, 11, 12	Daratumumab, Bortezomib, Lenalidomide, Dexamethasone	every 28 days × 4	Newly diagnosed transplant-eligible myeloma: 4 induction cycles, ASCT, 2 consolidation cycles, then D-R maintenance	PERSEUS, CEPHEUS
Dabrafenib + trametinib Dabrafenib 150 mg twice daily D1-28; Trametinib 2 mg once daily D1-28	Dabrafenib, Trametinib	every 28 days	BRAF V600-mutant melanoma (adjuvant 1 year or metastatic), NSCLC, anaplastic thyroid cancer and tumour-agnostic use	COMBI-AD, ROAR (anaplastic thyroid cancer cohort)
Docetaxel + prednisone Docetaxel 75 mg/m² D1; Prednisone 5 mg twice daily D1-21	Docetaxel, Prednisone	every 21 days × 6	Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer	CHAARTED (E3805), ARASENS, PEACE-1
Dose-dense AC → T ddAC-T Doxorubicin 60 mg/m² D1; Cyclophosphamide 600 mg/m² D1; Paclitaxel 175 mg/m² every 2 weeks × 4, or 80 mg/m² weekly × 12 D1	Doxorubicin, Cyclophosphamide, Paclitaxel	every 14 days × 4	Node-positive or high-risk early breast cancer, adjuvant or neoadjuvant	none
Dose-dense MVAC ddMVAC, accelerated MVAC Methotrexate 30 mg/m² D1; Vinblastine 3 mg/m² D2; Doxorubicin 30 mg/m² D2; Cisplatin 70 mg/m² D2	Methotrexate, Vinblastine, Doxorubicin, Cisplatin	every 14 days × 3-4	Muscle-invasive bladder cancer, cisplatin-eligible, before cystectomy	NIAGARA
Doxorubicin Doxorubicin 75 mg/m² D1	Doxorubicin	every 21 days × 6	Advanced soft-tissue sarcoma, first line	none
DRd (daratumumab + lenalidomide + dexamethasone) Daratumumab 16 mg/kg IV or 1,800 mg SC: weekly cycles 1-2, every 2 weeks cycles 3-6, then every 4 weeks D1, 8, 15, 22; Lenalidomide 25 mg once daily D1-21; Dexamethasone 40 mg weekly (20 mg over 75 years) D1, 8, 15, 22	Daratumumab, Lenalidomide, Dexamethasone	every 28 days	Newly diagnosed transplant-ineligible myeloma (MAIA); relapsed myeloma (POLLUX)	none
Enfortumab vedotin + pembrolizumab Enfortumab vedotin 1.25 mg/kg (maximum 125 mg) D1, 8; Pembrolizumab 200 mg D1	Enfortumab vedotin, Pembrolizumab	every 21 days	Locally advanced or metastatic urothelial cancer, first line, regardless of cisplatin eligibility	EV-302 / KEYNOTE-A39
Eribulin Eribulin 1.4 mg/m² (1.23 mg/m² as free base) D1, 8	Eribulin	every 21 days	Metastatic breast cancer after an anthracycline and a taxane; liposarcoma	none
Everolimus Everolimus 10 mg once daily D1-28	Everolimus	every 28 days	Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy	RADIANT-3 and RADIANT-4
FLOT Docetaxel 50 mg/m² D1; Oxaliplatin 85 mg/m² D1; Leucovorin (folinic acid) 200 mg/m² D1; Fluorouracil infusion 2,600 mg/m² D1, 2 (24 h infusion)	Docetaxel, Oxaliplatin, Leucovorin (folinic acid), Fluorouracil infusion	every 14 days × 4	Resectable gastric or gastro-oesophageal junction adenocarcinoma, cT2 or higher or node-positive	MATTERHORN
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T Fludarabine 30 mg/m² per day D1-3; Cyclophosphamide 500 mg/m² per day D1-3; CAR-T cells (axicabtagene, lisocabtagene, tisagenlecleucel) product-specific dose, e.g. 2 × 10⁶ CAR-positive cells/kg D6	Fludarabine, Cyclophosphamide, CAR-T cells	every 6 days	Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma	ZUMA-7, TRANSFORM, ELIANA
FOLFIRI Irinotecan 180 mg/m² D1; Leucovorin (folinic acid) 400 mg/m² D1; Fluorouracil bolus 400 mg/m² D1; Fluorouracil infusion 2,400 mg/m² D1, 2 (46 h infusion)	Irinotecan, Leucovorin (folinic acid), Fluorouracil bolus, Fluorouracil infusion	every 14 days	Metastatic colorectal first or second line (with bevacizumab, aflibercept, ramucirumab or an anti-EGFR antibody)	CRYSTAL & FIRE-3
FOLFIRINOX Oxaliplatin 85 mg/m² D1; Irinotecan 180 mg/m² D1; Leucovorin (folinic acid) 400 mg/m² D1; Fluorouracil bolus 400 mg/m² D1; Fluorouracil infusion 2,400 mg/m² D1, 2 (46 h infusion)	Oxaliplatin, Irinotecan, Leucovorin (folinic acid), Fluorouracil bolus, Fluorouracil infusion	every 14 days × 12	Metastatic pancreatic cancer, performance status 0-1	none
Gemcitabine + cisplatin GemCis Cisplatin 25 mg/m² (biliary) or 70 mg/m² day 1 (urothelial) D1, 8; Gemcitabine 1,000 mg/m² D1, 8	Cisplatin, Gemcitabine	every 21 days × 8	Advanced biliary tract cancer first line (with durvalumab or pembrolizumab); cisplatin-eligible urothelial cancer	ABC-02, TOPAZ-1, KEYNOTE-966
Gemcitabine + cisplatin (nasopharyngeal) Gemcitabine 1,000 mg/m² D1, 8; Cisplatin 80 mg/m² D1; Toripalimab (recurrent or metastatic, JUPITER-02) 240 mg D1	Gemcitabine, Cisplatin, Toripalimab	every 21 days × 3	Locoregionally advanced nasopharyngeal carcinoma, induction before chemoradiation; recurrent or metastatic disease with toripalimab	JUPITER-02
Gemcitabine + nab-paclitaxel nab-Paclitaxel 125 mg/m² D1, 8, 15; Gemcitabine 1,000 mg/m² D1, 8, 15	nab-Paclitaxel, Gemcitabine	every 28 days	Metastatic pancreatic cancer first line; adjuvant option when FOLFIRINOX is not tolerated	none
Gemcitabine monotherapy Gemcitabine 1,000 mg/m² D1, 8, 15	Gemcitabine	every 28 days × 6	Frail patients or adjuvant when combinations are not tolerated	none
High-dose cisplatin chemoradiation Cisplatin 100 mg/m² (weekly 40 mg/m² is the alternative) D1; Radiotherapy 2 Gy per fraction, 5 days a week D1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19	Cisplatin, Radiotherapy	every 21 days × 3	Locally advanced head and neck squamous cell carcinoma, definitive or postoperative (positive margins or extranodal extension)	RTOG 0129 (HPV analysis), NRG-HN002 & NRG-HN005 (HPV+ de-escalation)
High-dose melphalan and autologous stem-cell transplant Melphalan 200 mg/m² (140 mg/m² if over 70 or renal impairment) D1	Melphalan	single day × 1	Transplant-eligible myeloma after induction	none
Imatinib Imatinib 400 mg once daily with food (600-800 mg for KIT exon 9 GIST or accelerated phase) D1-28	Imatinib	every 28 days	Chronic-phase CML; adjuvant GIST for 3 years after resection of high-risk tumours; metastatic GIST	SSGXVIII/AIO (adjuvant imatinib in GIST)
Inotuzumab ozogamicin Inotuzumab ozogamicin 0.8 mg/m² day 1, 0.5 mg/m² days 8 and 15 (cycle 1); 0.5 mg/m² all doses once in remission D1, 8, 15	Inotuzumab ozogamicin	every 21 days	Relapsed or refractory CD22-positive B-ALL	INO-VATE ALL
Interval-compressed VDC/IE Vincristine 2 mg/m² (maximum 2 mg) D1; Doxorubicin 37.5 mg/m² per day (75 mg/m² per cycle; dactinomycin replaces it after 375 mg/m²) D1, 2; Cyclophosphamide 1,200 mg/m² with mesna D1; Ifosfamide 1,800 mg/m² per day with mesna D15-19; Etoposide 100 mg/m² per day D15-19	Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, Etoposide	every 28 days × 7	Localised Ewing sarcoma, 14 alternating cycles (induction then consolidation around local therapy)	Euro Ewing 2012, INT-0091 (Ewing sarcoma)
Intravesical BCG, induction and maintenance BCG one full-dose vial (reduced dose during shortages) D1	BCG	weekly × 6	High-risk non-muscle-invasive bladder cancer after complete TURBT	POTOMAC, SunRISe-1
KEYNOTE-522 (pembrolizumab + chemotherapy, then adjuvant pembrolizumab) Pembrolizumab 200 mg D1; Paclitaxel 80 mg/m² D1, 8, 15; Carboplatin AUC 5 day 1 (or AUC 1.5 weekly) D1; Doxorubicin 60 mg/m² (or epirubicin 90 mg/m²) D1; Cyclophosphamide 600 mg/m² D1	Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide	every 21 days × 4	Stage II-III triple-negative breast cancer	KEYNOTE-522
Lenalidomide maintenance Lenalidomide 10 mg once daily (15 mg after 3 months if tolerated) D1-21	Lenalidomide	every 28 days	After autologous transplant	none
MAP (methotrexate, doxorubicin, cisplatin) Cisplatin 120 mg/m² D1; Doxorubicin 37.5 mg/m² per day D1, 2; High-dose methotrexate 12 g/m² (maximum 20 g) with leucovorin rescue D22, 29 (4 h infusion)	Cisplatin, Doxorubicin, High-dose methotrexate	every 35 days × 2	Resectable high-grade osteosarcoma, patients under 40: 10 weeks before surgery, then postoperative cycles to about 29 weeks	none
mFOLFIRINOX (adjuvant) Oxaliplatin 85 mg/m² D1; Irinotecan 150 mg/m² D1; Leucovorin (folinic acid) 400 mg/m² D1; Fluorouracil infusion 2,400 mg/m² D1, 2 (46 h infusion)	Oxaliplatin, Irinotecan, Leucovorin (folinic acid), Fluorouracil infusion	every 14 days × 12	Resected pancreatic cancer, fit patients, started within 12 weeks of surgery	PRODIGE 24 / CCTG PA6
mFOLFOX6 FOLFOX Oxaliplatin 85 mg/m² D1; Leucovorin (folinic acid) 400 mg/m² D1; Fluorouracil bolus 400 mg/m² D1; Fluorouracil infusion 2,400 mg/m² D1, 2 (46 h infusion)	Oxaliplatin, Leucovorin (folinic acid), Fluorouracil bolus, Fluorouracil infusion	every 14 days × 12	Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line	PARADIGM, SUNLIGHT
Mirvetuximab soravtansine Mirvetuximab soravtansine 6 mg/kg adjusted ideal body weight D1	Mirvetuximab soravtansine	every 21 days	Folate receptor alpha-high platinum-resistant ovarian cancer, 1-3 prior lines	MIRASOL / GOG-3045
Mitomycin + fluorouracil chemoradiation Nigro regimen Mitomycin 10 mg/m² (maximum 20 mg) D1, 29; Fluorouracil infusion 1,000 mg/m² per day D1, 2, 3, 4, 29, 30, 31, 32 (96 h infusion); Radiotherapy 50.4-54 Gy in 28-30 fractions D1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39, 40	Mitomycin, Fluorouracil infusion, Radiotherapy	every 56 days × 1	Localised anal squamous cell carcinoma, definitive treatment	none
N-AVD (nivolumab + AVD) Nivolumab 240 mg (3 mg/kg under 18 years) D1, 15; Doxorubicin 25 mg/m² D1, 15; Vinblastine 6 mg/m² D1, 15; Dacarbazine 375 mg/m² D1, 15	Nivolumab, Doxorubicin, Vinblastine, Dacarbazine	every 28 days × 6	Stage III-IV classical Hodgkin lymphoma, age 12 and above	SWOG S1826
NALIRIFOX Liposomal irinotecan 50 mg/m² D1; Oxaliplatin 60 mg/m² D1; Leucovorin (folinic acid) 400 mg/m² D1; Fluorouracil infusion 2,400 mg/m² D1, 2 (46 h infusion)	Liposomal irinotecan, Oxaliplatin, Leucovorin (folinic acid), Fluorouracil infusion	every 14 days	Metastatic pancreatic cancer first line	NAPOLI 3
Niraparib maintenance Niraparib 200 mg once daily if weight under 77 kg or platelets under 150 × 10⁹/L; otherwise 300 mg D1-28	Niraparib	every 28 days × 3	Newly diagnosed advanced ovarian cancer after platinum response, regardless of BRCA status	PRIMA / ENGOT-OV26
Nivolumab + FOLFOX or CAPOX Nivolumab 240 mg (with FOLFOX) or 360 mg every 3 weeks with CAPOX D1; Oxaliplatin 85 mg/m² D1; Leucovorin (folinic acid) 400 mg/m² D1; Fluorouracil bolus 400 mg/m² D1; Fluorouracil infusion 2,400 mg/m² D1, 2 (46 h infusion)	Nivolumab, Oxaliplatin, Leucovorin (folinic acid), Fluorouracil bolus, Fluorouracil infusion	every 14 days	Unresectable or metastatic HER2-negative gastric, junctional or oesophageal adenocarcinoma, first line (benefit concentrated in PD-L1 CPS 5 or above)	CheckMate 649
Nivolumab + ipilimumab (melanoma) Ipilimumab 3 mg/kg D1; Nivolumab 1 mg/kg D1	Ipilimumab, Nivolumab	every 21 days × 4	Unresectable or metastatic melanoma, especially with brain metastases or PD-L1-negative disease	CheckMate 067, DREAMseq (ECOG-ACRIN EA6134)
Nivolumab + ipilimumab (mesothelioma) Nivolumab 360 mg every 3 weeks D1, 22; Ipilimumab 1 mg/kg every 6 weeks D1	Nivolumab, Ipilimumab	every 42 days	Unresectable pleural mesothelioma first line, especially non-epithelioid	CheckMate 743
Nivolumab + ipilimumab (RCC) Nivolumab 3 mg/kg D1; Ipilimumab 1 mg/kg D1	Nivolumab, Ipilimumab	every 21 days × 4	Untreated advanced clear-cell RCC, IMDC intermediate or poor risk	CheckMate 214
Nivolumab + ipilimumab + 2 cycles of platinum doublet Nivolumab 360 mg D1; Ipilimumab 1 mg/kg every 6 weeks D1; Platinum doublet by histology cycles 1-2 only D1	Nivolumab, Ipilimumab, Platinum doublet by histology	every 21 days	Metastatic NSCLC without EGFR/ALK alteration, first line	none
Nivolumab + relatlimab Nivolumab + relatlimab (fixed dose) 480 mg nivolumab / 160 mg relatlimab D1	Nivolumab + relatlimab	every 28 days	Unresectable or metastatic melanoma, first line	RELATIVITY-047
Olaparib (adjuvant, OlympiA) Olaparib 300 mg twice daily D1-28	Olaparib	every 28 days × 13	Germline BRCA1/2, HER2-negative, high-risk early breast cancer after chemotherapy	OlympiA
Olaparib maintenance Olaparib 300 mg twice daily D1-28	Olaparib	every 28 days × 2	Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum	SOLO-1, PROfound, POLO, PROpel
Osimertinib Osimertinib 80 mg once daily D1-28	Osimertinib	every 28 days	EGFR ex19del or L858R NSCLC: first line metastatic (FLAURA), adjuvant for 3 years after resection (ADAURA), after chemoradiation (LAURA)	FLAURA2, ADAURA, LAURA
Pegylated liposomal doxorubicin Pegylated liposomal doxorubicin 40 mg/m² (20 mg/m² every 2-3 weeks in Kaposi sarcoma) D1	Pegylated liposomal doxorubicin	every 28 days	Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma	none
Pembrolizumab + axitinib Pembrolizumab 200 mg D1; Axitinib 5 mg twice daily (titrate to 7 then 10 mg) D1-21	Pembrolizumab, Axitinib	every 21 days	Untreated advanced clear-cell RCC, any IMDC risk	KEYNOTE-426
Pembrolizumab + carboplatin + paclitaxel Pembrolizumab 200 mg D1; Carboplatin AUC 6 D1; Paclitaxel 200 mg/m² day 1, or nab-paclitaxel 100 mg/m² days 1, 8, 15 cycles 1-4 D1	Pembrolizumab, Carboplatin, Paclitaxel 200 mg/m² day 1, or nab-paclitaxel 100 mg/m² days 1, 8, 15	every 21 days × 4	Metastatic squamous NSCLC, first line	none
Pembrolizumab + cisplatin + fluorouracil Pembrolizumab 200 mg D1; Cisplatin 80 mg/m² D1; Fluorouracil infusion 800 mg/m² per day D1-5 (120 h infusion)	Pembrolizumab, Cisplatin, Fluorouracil infusion	every 21 days	Advanced oesophageal or Siewert type 1 junctional cancer, first line	KEYNOTE-590
Pembrolizumab + pemetrexed + platinum Pembrolizumab 200 mg D1; Pemetrexed 500 mg/m² D1; Carboplatin AUC 5 or cisplatin 75 mg/m² day 1, cycles 1-4 D1	Pembrolizumab, Pemetrexed, Carboplatin AUC 5 or cisplatin 75 mg/m²	every 21 days × 4	Metastatic non-squamous NSCLC without EGFR/ALK alteration, first line, any PD-L1	KEYNOTE-024 & KEYNOTE-189
Pembrolizumab + platinum + fluorouracil Pembrolizumab 200 mg D1; Cisplatin 100 mg/m² or carboplatin AUC 5 day 1 D1; Fluorouracil infusion 1,000 mg/m² per day D1-4 (96 h infusion)	Pembrolizumab, Cisplatin 100 mg/m² or carboplatin AUC 5, Fluorouracil infusion	every 21 days	Recurrent or metastatic head and neck squamous cell carcinoma, first line	KEYNOTE-048, EXTREME
Pembrolizumab + platinum + paclitaxel ± bevacizumab (cervical) Pembrolizumab 200 mg D1; Paclitaxel 175 mg/m² D1; Cisplatin 50 mg/m² or carboplatin AUC 5 day 1 D1; Bevacizumab (optional) 15 mg/kg D1	Pembrolizumab, Paclitaxel, Cisplatin 50 mg/m² or carboplatin AUC 5, Bevacizumab	every 21 days	Persistent, recurrent or metastatic cervical cancer, PD-L1 CPS 1 or above	KEYNOTE-826
Pembrolizumab monotherapy Pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks D1	Pembrolizumab	every 21 days	Adjuvant melanoma stage IIB-IV (1 year); PD-L1 TPS 50% or above NSCLC; MSI-high tumours; recurrent head and neck (CPS 1 or above)	KEYNOTE-006, KEYNOTE-716, KEYNOTE-024 & KEYNOTE-189, KEYNOTE-177, KEYNOTE-048
Pola-R-CHP Polatuzumab vedotin 1.8 mg/kg D1; Rituximab 375 mg/m² D1; Cyclophosphamide 750 mg/m² D1; Doxorubicin 50 mg/m² D1; Prednisone 100 mg once daily D1-5	Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone	every 21 days × 6	Untreated DLBCL, IPI 2-5	POLARIX
R-CHOP Rituximab 375 mg/m² D1; Cyclophosphamide 750 mg/m² D1; Doxorubicin 50 mg/m² D1; Vincristine 1.4 mg/m² (maximum 2 mg) D1; Prednisone 100 mg once daily D1-5	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone	every 21 days × 6	Diffuse large B-cell lymphoma, first line (6 cycles; 3-4 with radiotherapy for limited stage)	POLARIX
R-ICE Rituximab 375 mg/m² D1; Etoposide 100 mg/m² D1-3; Carboplatin AUC 5 (maximum 800 mg) D2; Ifosfamide 5,000 mg/m² with mesna D2 (24 h infusion)	Rituximab, Etoposide, Carboplatin, Ifosfamide	every 14 days × 2-3	Relapsed or refractory DLBCL, salvage before autologous transplant (late relapse) or bridging	ZUMA-7, TRANSFORM
Sacituzumab govitecan Sacituzumab govitecan 10 mg/kg D1, 8	Sacituzumab govitecan	every 21 days	Metastatic TNBC after two lines (one for metastatic disease); HR-positive after endocrine therapy and two chemotherapies	ASCENT, TROPiCS-02
STRIDE (tremelimumab + durvalumab) Tremelimumab 300 mg single priming dose D1; Durvalumab 1,500 mg D1	Tremelimumab, Durvalumab	every 28 days	Unresectable hepatocellular carcinoma, first line	HIMALAYA
Sunitinib 4/2 Sunitinib 50 mg once daily, 4 weeks on / 2 weeks off (37.5 mg continuous in NET) D1-28	Sunitinib	every 42 days	Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET	CheckMate 214
Tarlatamab Tarlatamab 1 mg day 1, 10 mg day 8 and day 15, then 10 mg every 2 weeks D1, 8	Tarlatamab	every 14 days	Extensive-stage SCLC after platinum-based chemotherapy	DeLLphi-304
TC (docetaxel + cyclophosphamide) Docetaxel 75 mg/m² D1; Cyclophosphamide 600 mg/m² D1	Docetaxel, Cyclophosphamide	every 21 days × 4	Early breast cancer when an anthracycline is not wanted	none
TCHP Docetaxel 75 mg/m² D1; Carboplatin AUC 6 D1; Trastuzumab 8 mg/kg loading then 6 mg/kg D1; Pertuzumab 840 mg loading then 420 mg D1	Docetaxel, Carboplatin, Trastuzumab, Pertuzumab	every 21 days × 6	Stage II-III HER2-positive breast cancer, neoadjuvant	DESTINY-Breast11
Teclistamab Teclistamab step-up 0.06 mg/kg and 0.3 mg/kg, then 1.5 mg/kg weekly D1	Teclistamab	weekly	Relapsed or refractory myeloma after 3 or more lines including a PI, IMiD and CD38 antibody	MajesTEC-1, MajesTEC-3
Temozolomide chemoradiation then adjuvant temozolomide (Stupp) Temozolomide (concurrent) 75 mg/m² daily for 42 days with radiotherapy 60 Gy in 30 fractions D1-28; Temozolomide (adjuvant) 150 mg/m² cycle 1, then 200 mg/m² D1-5; Radiotherapy 2 Gy per fraction, 5 days a week D1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26	Temozolomide, Temozolomide, Radiotherapy	every 28 days × 6	Newly diagnosed glioblastoma, age 70 or under, performance status 0-2 (hypofractionated variants for older patients)	EORTC 26981 / NCIC CE.3 (Stupp trial), EF-14
THP (docetaxel + trastuzumab + pertuzumab) Docetaxel 75 mg/m² D1; Trastuzumab 8 mg/kg loading then 6 mg/kg D1; Pertuzumab 840 mg loading then 420 mg D1	Docetaxel, Trastuzumab, Pertuzumab	every 21 days	HER2-positive metastatic breast cancer first line, then HP maintenance	CLEOPATRA, DESTINY-Breast09
Topotecan Topotecan 1.5 mg/m² IV (or 2.3 mg/m² oral) D1-5	Topotecan	every 21 days	Relapsed SCLC; platinum-resistant ovarian or cervical cancer	none
TPF induction Docetaxel 75 mg/m² D1; Cisplatin 75 mg/m² D1; Fluorouracil infusion 750 mg/m² per day D1-5 (120 h infusion)	Docetaxel, Cisplatin, Fluorouracil infusion	every 21 days × 3-4	Locally advanced head and neck cancer where induction is chosen (larynx preservation, bulky nodes)	none
Trabectedin Trabectedin 1.5 mg/m² through a central line D1 (24 h infusion)	Trabectedin	every 21 days	Liposarcoma and leiomyosarcoma after an anthracycline	none
Trastuzumab deruxtecan 5.4 mg/kg Trastuzumab deruxtecan 5.4 mg/kg (6.4 mg/kg in gastric cancer) D1	Trastuzumab deruxtecan	every 21 days	HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC	DESTINY-Breast03, DESTINY-Breast04, DESTINY-Breast06
Trifluridine/tipiracil + bevacizumab Trifluridine/tipiracil 35 mg/m² twice daily D1, 2, 3, 4, 5, 8, 9, 10, 11, 12; Bevacizumab 5 mg/kg D1, 15	Trifluridine/tipiracil, Bevacizumab	every 28 days	Refractory metastatic colorectal cancer after two lines	SUNLIGHT
Venetoclax + azacitidine Azacitidine 75 mg/m² D1-7; Venetoclax 100 mg day 1, 200 mg day 2, then 400 mg daily (cycle 1 ramp-up); often days 1-21 from cycle 2 D1-28	Azacitidine, Venetoclax	every 28 days	Newly diagnosed AML unfit for intensive chemotherapy	VIALE-A
Venetoclax + obinutuzumab (fixed duration) Obinutuzumab 100 mg day 1, 900 mg day 2, 1,000 mg days 8 and 15 (cycle 1); 1,000 mg day 1 cycles 2-6 D1, 2, 8, 15; Venetoclax 20 → 50 → 100 → 200 → 400 mg weekly ramp-up from cycle 1 day 22, then 400 mg daily D22-28	Obinutuzumab, Venetoclax	every 28 days × 12	Untreated CLL, all fitness levels	CLL14, CLL13 / GAIA
VRd Bortezomib 1.3 mg/m² D1, 4, 8, 11; Lenalidomide 25 mg once daily D1-14; Dexamethasone 20 mg D1, 2, 4, 5, 8, 9, 11, 12	Bortezomib, Lenalidomide, Dexamethasone	every 21 days × 8	Newly diagnosed myeloma (with daratumumab as D-VRd in transplant-eligible patients)	PERSEUS, IMROZ
Weekly cisplatin chemoradiation (with pembrolizumab for high-risk disease) Cisplatin 40 mg/m² (maximum 70 mg) D1; Pembrolizumab (KEYNOTE-A18) 200 mg every 3 weeks × 5, then 400 mg every 6 weeks × 15 D1; Radiotherapy 45-50.4 Gy external beam plus brachytherapy D1-5	Cisplatin, Pembrolizumab, Radiotherapy	weekly × 5-6	Locally advanced cervical cancer (FIGO IB2-IVA); pembrolizumab for FIGO 2014 III-IVA or node-positive	KEYNOTE-A18 / ENGOT-cx11 / GOG-3047, INTERLACE
Weekly paclitaxel Paclitaxel 80 mg/m² D1, 8, 15; Bevacizumab (optional, AURELIA) 10 mg/kg D1, 15	Paclitaxel, Bevacizumab	every 28 days	Platinum-resistant ovarian cancer (with or without bevacizumab); metastatic breast cancer	MIRASOL / GOG-3045

How to read a row

Components are the published protocol doses for a typical adult; hover a drug for its dose, click for its page. The cycle column gives the repeat interval and the planned count, so “every 14 days × 12” is six months. Emetogenicity follows the NCCN Antiemesis and MASCC-ESMO classes for the most emetogenic component; G-CSF follows the ASCO 2015 and NCCN febrile-neutropenia bands. Every regimen page cites its pivotal publication or the NCCN guideline that lists it.

What this is not

Not a prescribing system. Doses are adjusted for renal and hepatic function, age, prior toxicity and local protocol; several regimens exist in more than one published variant and the one shown is named in the source. Check the current label and your institution’s protocol before treating. The calculators cover body surface area, carboplatin AUC and creatinine clearance; interactions flags the common drug-drug problems.